FDA Accepts Supplement Application for TWIRLA by AGILE
The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.
Asset / Drug
Drug and asset intelligence for AGILE with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.